Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(3), С. 172 - 172

Опубликована: Март 4, 2025

Chemotherapy for cancer frequently uses platinum-based medications, including oxaliplatin, carboplatin, and cisplatin; however, due to their high systemic toxicity, lack of selectivity, drug resistance, other side effects, medications have very limited clinical application. As a first-line medication in antitumor therapy, oxaliplatin must be administered minimize effects while achieving anticancer objectives. A new CDC7 inhibitor called XL413 has demonstrated promising therapeutic variety malignant tumors may properties. This offers fresh viewpoint on how lessen resistance and, specifically, increase the potency already prescribed therapies. In this paper, current developments therapy are discussed, along with many mechanisms oxaliplatin’s treatment challenges, related approaches. We conducted more research that arose during chemotherapy searched ways it order enhance its chemotherapeutic performance. Ultimately, we studied distinct routes relate one another. Meanwhile, XL413, novel inhibitor, perspective possibilities developing approaches innovation point. The search terms “Oxaliplatin, treatment,” etc., were applied X-MOL PubMed databases review’s literature search. Boolean logic was then employed maximize approach. These can offer thorough data cover broad range biological publications. Excluded publications works low relevance, duplicates, or those insufficient information. mechanism effect, amelioration, role main topics 140 ultimately included analysis.

Язык: Английский